Harrow, Inc. Files 8-K/A Amendment
Ticker: HROW · Form: 8-K/A · Filed: Oct 1, 2025 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | 8-K/A |
| Filed Date | Oct 1, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-reporting, exhibits
Related Tickers: HROW
TL;DR
Harrow filed an amendment to an 8-K, mostly technical stuff, check exhibits for details.
AI Summary
Harrow, Inc. filed an amendment (8-K/A) on October 1, 2025, related to events on September 24, 2025. The filing primarily concerns financial statements and exhibits, with no specific new financial transactions or material events detailed in the provided text.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be important for understanding the company's financial reporting.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not appear to disclose new material events or financial changes.
Key Players & Entities
- HARROW, INC. (company) — Registrant
- 001-35814 (company) — SEC File Number
- 45-0567010 (company) — EIN
- September 24, 2025 (date) — Earliest event reported date
- October 1, 2025 (date) — Filing date
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment (Amendment No. 1) to a previous Current Report on Form 8-K, primarily concerning financial statements and exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is September 24, 2025.
When was this 8-K/A filing submitted to the SEC?
The filing was submitted on October 1, 2025.
What is Harrow, Inc.'s SIC code?
Harrow, Inc.'s Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
What are some former names of Harrow, Inc. mentioned in the filing?
Former names mentioned include HARROW HEALTH, INC., Imprimis Pharmaceuticals, Inc., and TRANSDEL PHARMACEUTICALS INC.
Filing Stats: 750 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2025-10-01 07:39:13
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HROW The Nasdaq
Filing Documents
- form8-ka.htm (8-K/A) — 48KB
- ex2-1.htm (EX-2.1) — 632KB
- ex10-1.htm (EX-10.1) — 62KB
- 0001493152-25-016473.txt ( ) — 1052KB
- hrow-20250924.xsd (EX-101.SCH) — 4KB
- hrow-20250924_def.xml (EX-101.DEF) — 26KB
- hrow-20250924_lab.xml (EX-101.LAB) — 36KB
- hrow-20250924_pre.xml (EX-101.PRE) — 25KB
- form8-ka_htm.xml (XML) — 8KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this amended report to be signed on its behalf by the undersigned hereunto duly authorized. HARROW, INC. Dated: October 1, 2025 By: /s/ Andrew R. Boll Andrew R. Boll President and Chief Financial Officer